Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma

PURPOSE: The LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies. METHODS: This was a retrospective review among 21 medical centers of 150 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Cid, Jeronimo Rafael, Campos-Gomez, Saul, García-Montes, Vanessa, Magallanes-Maciel, Manuel, Flores-Mariñelarena, Rodrigo Rafael, Fernández-Garibay, Valeria Michelle, González-Espinoza, Iván Romarico, Ceja-García, Juan Paulo, Cázarez-Price, Juan Carlos, Martínez-Barrera, Luis, Barriguete-Parra, Leopoldo, Zuloaga-Fernandez, Carlos Jose, Kuri-Exsome, Roberto, Suárez-García, David, Gonzalez-Villanueva, Jorge Ignacio, Flores-Anaya, Noé, Acevedo-Delgado, Jose Antonio, Astorga-Ramos, Alma Magdalena, Gerson-Cwilich, Raquel, Villalobos-Prieto, Alberto, Rodríguez-Silva, Claudia, Noriega-Iriondo, Maria Fernanda, Vázquez-Cortés, Leticia, Perales-Rodríguez, Eusebio, Acosta-Espinoza, Alicia, Perez-Lozano, Yareni, Capdeville-García, Daniel, Alatorre-Alexander, Jorge Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113104/
https://www.ncbi.nlm.nih.gov/pubmed/32196388
http://dx.doi.org/10.1200/JGO.19.00330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113104/
https://www.ncbi.nlm.nih.gov/pubmed/32196388
http://dx.doi.org/10.1200/JGO.19.00330

Ejemplares similares